Abstract

Background: Burn injuries are one of the main causes of mortality and morbidity throughout the world and burn patients have higher chances for infection due to their decreased immune resistance. Levamisole, as an immunomodulation agent, stimulates the immune response against infection. Materials and Methods: This randomized clinical trial was conducted in Motahari Burn Center, Tehran, Iran. Patients who had second-or third-degree burn with involvement of more than 50 of total body surface area (TBSA) were studied. The levamisole group received levamisole tablet, 100 mg per day. Meantime, both the levamisole and control groups received the standard therapy of the Burn Center, based on a standard protocol. Then, the outcome of the patients was evaluated. Results: 237 patients entered the study. After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group and 85 in the treatment group. The mean age of all patients (between 13 to 64 years) was 33.29 +/- 11.39 years (Mean +/- SD), and it was 33.86 +/- 11.45 years in the control group and 32.57 +/- 11.32 years in the treatment group. The mean percentage of TBSA burn was 64.50 +/- 14.34 and 68.58 +/- 14.55 for the levamisole and control groups, respectively, with the range of 50-100 and 50-95 TBSA. The mortality rate was 68 (61.8) patients in the control group and 50 (58.8) patients in the treatment group (P = 0.8). Conclusion: According to this study, there was no significant relationship between improvement of mortality and levamisole consumption.